Navigation Links
Ohio Becoming Global Hub for Biomedical Research and Commercialization
Date:11/12/2008

BioInnovation Institute combines Ohio's strengths in the polymer industry

and medical fields to spark biomedical innovation

COLUMBUS, Ohio, Nov. 12 /PRNewswire/ -- Ohio aims to become a global hub for biomedical research, commercialization and innovation after the recent launch of the BioInnovation Institute located in Akron, Ohio. According to the Ohio Business Development Coalition, the nonprofit organization that markets the state for capital investment, the BioInnovation Institute will bring together Ohio's world-class organizations, researchers and educators in the polymer industry and biomaterials and biomedical fields to generate the next generation of life-enhancing innovation for the 21st century.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071107/CLW113LOGO )

The result of public-private partnerships from organizations throughout the state, the BioInnovation Institute will create a nationally distinctive center of excellence by drawing talent from across the globe, increase annual funding for Ohio's polymer industry and biomedical research, increase investment by national firms into the state and bring thousands of new jobs to Ohio by 2018.

"The BioInnovation Institute in Akron is uniquely positioned to meld the state's traditional strengths in research and education in both the polymer industry and biomedical excellence to create transformational new technologies with a direct impact on the people we collectively serve," said William H. Considine, chairman of the BioInnovation Institute and president and chief executive officer of Akron Children's Hospital. "Our vision of making Akron, and the state of Ohio, a national leader in the biomedical field is absolutely attainable given our intellectual, educational, research and commercial strengths."

Founders of the BioInnovation Institute include Akron Children's Hospital, Akron General Health System, Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM), Summa Health System and The University of Akron. Faculty members will include researchers, physicians and educators from the partner organizations.

The John S. and James L. Knight Foundation led the funding effort to create the BioInnovation Institute with a $20 million grant. Supporting partners have secured $80 million overall for the project. The state of Ohio also has contributed more than $8 million through the Ohio Third Frontier Project, a 10-year, $1.6 billion initiative to help catalyze connections between companies and academia. The project is the state's largest-ever commitment to expanding high-tech research capabilities and promoting innovation and company formation that will create high-paying jobs for generations to come.

"Ohio leads the world in advanced materials capability and is rapidly becoming a global leader in the bioscience industry. The cross fertilization of knowledge between these two industries has the potential to lead to commercial innovations that will dramatically improve lives. It will also stimulate new capital investment in our economy," said Ed Burghard, executive director of the Ohio Business Development Coalition. "Companies are attracted to the bottom-line benefits generated from the superior work-life balance found in Ohio. Ohio's low-cost, low stress communities and combination of micropolitan and metropolitan cities provides executives and employees the resources and time to make any ambition achievable. Ohio truly is the state of perfect balance."

About the Ohio Business Development Coalition

The Ohio Business Development Coalition is a nonprofit organization that markets the state for capital investment. The OBDC provides marketing strategy and implementation to support Ohio's economic development efforts. For more information on business development or business relocation, visit http://www.ohiomeansbusiness.com.


'/>"/>
SOURCE Ohio Business Development Coalition
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alkemists Sets The Bar, Becoming a 'Green' Analytical Laboratory
2. Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts
3. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
4. New Generation Biofuels CEO to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
6. AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008
7. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
8. Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference
11. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):